We are pleased to announce you a great achievement: in view of the acceptance of a study of ours on fibromyalgia, the Hyperbaric Centre of Ravenna will participate into the third international conference on hyperbaric oxygen therapy and brain, organized by the Israeli Society for Hyperbaric and Diving Medicine (ISHDM) from 18 to 20 May 2017.
Dr. Longobardi’s speech is planned on Friday, May 19 at 5:45 pm.
The work’s title is “HBOT in the Clinical Pathway, as a reliable integrative treatment for fibromyalgia” and it will be discussed by our Medical Director, Dr. Pasquale Longobardi.
The study has been carried out by our team of professionals: P. Longobardi, N. Belkacem, F. Fontana, E. Grazzini, M. Vassura, M. Gaudenzi, D. Bandini and K. Hoxha, who worked side by side during last year.
In 2016, 42 patients affected by fibromyalgia were evaluated to be admitted to the fibromyalgia clinical pathway developed by the Hyperbaric Centre of Ravenna. 15 of them were considered to be valid to follow a HBOT pathway; the exclusion of many of them was primarily due to economic and logistic reasons.
The clinical trial revealed an improvement in 13 women (87%), who followed a pathway with HBOT. Pain was reduced of intensity in the 50% of patients (VAS average -4.2 and race points -4.75) and of frequency in the 30% of patients. Quantity and quality of sleep, asthenia and intestinal disorders improved when present. The SPECT exam revealed an improvement of altered cerebral perfusion, thalamus hypo-perfusion and caudate nucleus.
We are really happy about this news, which, pending further studies and confirmations, provides a partial evidence of the fact that HBOT can be a valid help during multidisciplinary treatment pathways. Once and again the Hyperbaric Centre of Ravenna demonstrates the value of its work in an international context.